Publication | Open Access

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival

5-Year SurvivalBreast OncologyOncologyStage IiPathologyNeoadjuvant TreatmentBreast CancerCancer TreatmentMedicine